This document is a publication of a European patent application (EP4518970A2) filed by Scholar Rock, Inc. The patent pertains to the use of a myostatin inhibitor for the treatment of spinal muscular atrophy (SMA), detailing specific chemical entities and their therapeutic applications. The publication date is March 18, 2026.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers operating in the SMA therapeutic area, as it relates to intellectual property and potential future market exclusivity for specific treatments. Compliance officers should note this publication for competitive intelligence and potential licensing considerations.